Cost of illness due to respiratory syncytial virus acute lower respiratory tract infection among infants hospitalized in Argentina.
Acute lower respiratory tract infection
Cost of illness
Direct medical cost
Respiratory syncytial virus
Journal
BMC public health
ISSN: 1471-2458
Titre abrégé: BMC Public Health
Pays: England
ID NLM: 100968562
Informations de publication
Date de publication:
10 Feb 2024
10 Feb 2024
Historique:
received:
25
09
2023
accepted:
24
01
2024
medline:
10
2
2024
pubmed:
10
2
2024
entrez:
9
2
2024
Statut:
epublish
Résumé
Information is scarce regarding the economic burden of respiratory syncytial virus (RSV) disease in low-resource settings. This study aimed to estimate the cost per episode of hospital admissions due to RSV severe disease in Argentina. This is a prospective cohort study that collected information regarding 256 infants under 12 months of age with acute lower respiratory tract infection (ALRTI) due to RSV in two public hospitals of Buenos Aires between 2014 and 2016. Information on healthcare resource use was collected from the patient's report and its associated costs were estimated based on the financial database and account records of the hospitals. We estimated the total cost per hospitalization due to RSV using the health system perspective. The costs were estimated in US dollars as of December 2022 (1 US dollar = 170 Argentine pesos). The mean costs per RSV hospitalization in infants was US$587.79 (95% confidence interval [CI] $535.24 - $640.33). The mean costs associated with pediatric intensive care unit (PICU) admission more than doubled from those at regular pediatric wards ($1,556.81 [95% CI $512.21 - $2,601.40] versus $556.53 [95% CI $514.59 - $598.48]). This study shows the direct economic impact of acute severe RSV infection on the public health system in Argentina. The estimates obtained from this study could be used to inform cost-effectiveness analyses of new preventive RSV interventions being developed.
Sections du résumé
BACKGROUND
BACKGROUND
Information is scarce regarding the economic burden of respiratory syncytial virus (RSV) disease in low-resource settings. This study aimed to estimate the cost per episode of hospital admissions due to RSV severe disease in Argentina.
METHODS
METHODS
This is a prospective cohort study that collected information regarding 256 infants under 12 months of age with acute lower respiratory tract infection (ALRTI) due to RSV in two public hospitals of Buenos Aires between 2014 and 2016. Information on healthcare resource use was collected from the patient's report and its associated costs were estimated based on the financial database and account records of the hospitals. We estimated the total cost per hospitalization due to RSV using the health system perspective. The costs were estimated in US dollars as of December 2022 (1 US dollar = 170 Argentine pesos).
RESULTS
RESULTS
The mean costs per RSV hospitalization in infants was US$587.79 (95% confidence interval [CI] $535.24 - $640.33). The mean costs associated with pediatric intensive care unit (PICU) admission more than doubled from those at regular pediatric wards ($1,556.81 [95% CI $512.21 - $2,601.40] versus $556.53 [95% CI $514.59 - $598.48]).
CONCLUSIONS
CONCLUSIONS
This study shows the direct economic impact of acute severe RSV infection on the public health system in Argentina. The estimates obtained from this study could be used to inform cost-effectiveness analyses of new preventive RSV interventions being developed.
Identifiants
pubmed: 38336643
doi: 10.1186/s12889-024-17878-3
pii: 10.1186/s12889-024-17878-3
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
427Informations de copyright
© 2024. The Author(s).
Références
Li Y, Wang X, Blau DM, et al. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in children younger than 5 years in 2019: a systematic analysis. Lancet. 2022;399:2047–64.
doi: 10.1016/S0140-6736(22)00478-0
pubmed: 35598608
pmcid: 7613574
Shi T, McAllister DA, O’Brien KL, et al. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015: a systematic review and modelling study. Lancet. 2017;390:946–58.
doi: 10.1016/S0140-6736(17)30938-8
pubmed: 28689664
pmcid: 5592248
Caballero MT, Polack FP. Respiratory syncytial virus is an “opportunistic” killer. Pediatr Pulmonol. 2018;53:664–7.
doi: 10.1002/ppul.23963
pubmed: 29461021
pmcid: 5947624
Srikantiah P, Vora P, Klugman KP. Assessing the Full Burden of Respiratory Syncytial Virus in Young Infants in Low- and Middle-Income Countries: The Importance of Community Mortality Studies. Clin Infect Dis. 2021;73:S177–9.
doi: 10.1093/cid/ciab486
pubmed: 34472571
pmcid: 8411251
Mazur NI, Löwensteyn YN, Willemsen JE, et al. Global respiratory syncytial virus-related infant community deaths. Clin Infect Dis. 2021;73:S229–37.
doi: 10.1093/cid/ciab528
pubmed: 34472576
pmcid: 8411255
Caballero MT, Bianchi AM, Grigaites SD, et al. Community mortality due to respiratory syncytial virus in argentina: population-based surveillance study. Clin Infect Dis. 2021;73:S210–7.
doi: 10.1093/cid/ciab497
pubmed: 34472572
pmcid: 8411253
Gill CJ, Mwananyanda L, MacLeod WB, et al. Infant deaths from respiratory syncytial virus in Lusaka, Zambia from the ZPRIME study: a 3-year, systematic, post-mortem surveillance project. Lancet Glob Health. 2022;10:e269–77.
doi: 10.1016/S2214-109X(21)00518-0
pubmed: 35063114
pmcid: 8789563
Simões EAF, Dani V, Potdar V, et al. Mortality From Respiratory Syncytial Virus in Children Under 2 Years of Age: a prospective community cohort study in rural Maharashtra. India Clinical Infectious Diseases. 2021;73:S193-202.
doi: 10.1093/cid/ciab481
pubmed: 34472578
Zhang S, Akmar LZ, Bailey F, et al. Cost of Respiratory Syncytial Virus-Associated Acute Lower Respiratory Infection Management in Young Children at the Regional and Global Level: a systematic review and meta-analysis. J Infect Dis. 2020;222:S680–7.
doi: 10.1093/infdis/jiz683
pubmed: 32227101
Geoghegan S, Erviti A, Caballero MT, et al. Mortality due to respiratory syncytial virus. Burden and risk factors. Am J Respir Crit Care Med. 2017;195:96–103.
doi: 10.1164/rccm.201603-0658OC
pubmed: 27331632
Group* TIm-RS. Palivizumab, a Humanized Respiratory Syncytial Virus Monoclonal Antibody, Reduces Hospitalization From Respiratory Syncytial Virus Infection in High-risk Infants. Pediatrics. 1998;102:531–7.
doi: 10.1542/peds.102.3.531
COMMITTEE ON INFECTIOUS DISEASES AND BRONCHIOLITIS GUIDELINES COMMITTEE, Brady MT, Byington CL, et al. Updated Guidance for Palivizumab Prophylaxis Among Infants and Young Children at Increased Risk of Hospitalization for Respiratory Syncytial Virus Infection. Pediatrics. 2014;134:415–20.
doi: 10.1542/peds.2014-1665
Cromer D, van Hoek AJ, Newall AT, Pollard AJ, Jit M. Burden of paediatric respiratory syncytial virus disease and potential effect of different immunisation strategies: a modelling and cost-effectiveness analysis for England. Lancet Public Health. 2017;2:e367–74.
doi: 10.1016/S2468-2667(17)30103-2
pubmed: 28804787
pmcid: 5541134
Commissioner O of the. FDA Approves New Drug to Prevent RSV in Babies and Toddlers. FDA. 2023; published online July 18. https://www.fda.gov/news-events/press-announcements/fda-approves-new-drug-prevent-rsv-babies-and-toddlers (Accessed 15 Aug 2023).
Hammitt LL, Dagan R, Yuan Y, et al. Nirsevimab for Prevention of RSV in Healthy Late-Preterm and Term Infants. N Engl J Med. 2022;386:837–46.
doi: 10.1056/NEJMoa2110275
pubmed: 35235726
U.S. FDA Approves ABRYSVO
Dvorkin J, De Luca J, Alvarez-Paggi D, Caballero MT. Responding to Higher-Than-Expected Infant Mortality Rates from Respiratory Syncytial Virus (RSV): Improving Treatment and Reporting Strategies. Infect Drug Resist. 2023;16:595–605.
doi: 10.2147/IDR.S373584
pubmed: 36733921
pmcid: 9888399
RSV Vaccine and mAb Snapshot. https://www.path.org/resources/rsv-vaccine-and-mab-snapshot/ (Accessed 23 Aug 2023).
Wittenauer R, Pecenka C, Baral R. Cost of childhood RSV management and cost-effectiveness of RSV interventions: a systematic review from a low- and middle-income country perspective. BMC Med. 2023;21:121.
doi: 10.1186/s12916-023-02792-z
pubmed: 37004038
pmcid: 10067246
Marcone DN, Durand LO, Azziz-Baumgartner E, et al. Incidence of viral respiratory infections in a prospective cohort of outpatient and hospitalized children aged ≤5 years and its associated cost in Buenos Aires. Argentina BMC Infect Dis. 2015;15:447.
doi: 10.1186/s12879-015-1213-4
pubmed: 26497393
Jo C. Cost-of-illness studies: concepts, scopes, and methods. Clin Mol Hepatol. 2014;20:327–37.
doi: 10.3350/cmh.2014.20.4.327
pubmed: 25548737
pmcid: 4278062
Larg A, Moss JR. Cost-of-illness studies: a guide to critical evaluation. Pharmacoeconomics. 2011;29:653–71.
doi: 10.2165/11588380-000000000-00000
pubmed: 21604822
Mejia N, Ramani E, Pallas SW, Song D, Abimbola T, Mogasale V. Methodological considerations for cost of illness studies of enteric fever. Clin Infect Dis. 2020;71:S111–9.
doi: 10.1093/cid/ciaa481
pubmed: 32725239
pmcid: 7388717
Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)—A metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009;42:377–81.
doi: 10.1016/j.jbi.2008.08.010
pubmed: 18929686
Rubinstein A, Zerbino MC, Cejas C, López A. Making Universal Health Care Effective in Argentina: a blueprint for reform. Health Syst Reform. 2018;4:203–13.
doi: 10.1080/23288604.2018.1477537
pubmed: 30067439
Macinko J, Montenegro H, Nebot Adell C, Etienne C. Grupo de Trabajo de Atención Primaria de Salud de la Organización Panamericana de la Salud [Renewing primary health care in the Americas]. Rev Panam Salud Publica. 2007;21:73–84.
pubmed: 17565795
Tipo de cobertura de salud de la población (en porcentaje). https://www.estadisticaciudad.gob.ar/si/genero/principal-indicador?indicador=tip_cob_sal (Accessed 22 Aug 2022).
Madhi SA, Polack FP, Piedra PA, et al. Respiratory Syncytial Virus Vaccination during Pregnancy and Effects in Infants. N Engl J Med. 2020; published online July 29 https://doi.org/10.1056/NEJMoa1908380 .
Atwell JE, Geoghegan S, Karron RA, Polack FP. Clinical predictors of critical lower respiratory tract illness due to respiratory syncytial virus in infants and children: data to inform case definitions for efficacy trials. J Infect Dis. 2016;214:1712–6.
doi: 10.1093/infdis/jiw447
pubmed: 27655869
Recommendations for the use of oxygen in COVID 19 patients. 2021. Ministry of Health, Argentina. https://bancos.salud.gob.ar/sites/default/files/2021-05/Recomendaciones_para_el_uso_de_oxigeno_en_pacientes_COVID%2019.pdf . .
Griffiths, U.; Rheingans, R.; Walker, D. Guidelines for estimating the economic burden of diarrhoeal disease with focus on assessing the impact of rotavirus diarrhoea. World Health Organization, Geneva, Switzerland. 2005. https://extranet.who.int/libdoc.html?ua=1 (Accessed 12 May 2017).
Ferolla FM, Hijano DR, Acosta PL, et al. Macronutrients during pregnancy and life-threatening respiratory syncytial virus infections in children. Am J Respir Crit Care Med. 2013;187:983–90.
doi: 10.1164/rccm.201301-0016OC
pubmed: 23449690
Caballero MT, Bianchi AM, Nuño A, et al. Mortality associated with acute respiratory infections among children at home. J Infect Dis. 2019;219:358–64.
doi: 10.1093/infdis/jiy517
pubmed: 30165655
Instituto Nacional de Estadística y Censos (INDEC), Analía Calero, Georgina Giglio. Valorización mensual de la canasta básica alimentaria y de la canasta básica total. Gran Buenos Aires. Informes técnicos. Condiciones de Vida. 2022;7(7), published online Dec. https://www.indec.gob.ar/uploads/informesdeprensa/canasta_01_23DF5760FF57.pdf .
Caballero MT, Polack FP, Stein RT. Viral bronchiolitis in young infants: new perspectives for management and treatment. Jornal de Pediatria. 2017;93:75–83.
doi: 10.1016/j.jped.2017.07.003
pubmed: 28859915
Lucion MF, Juarez MD, Viegas M, et al. Virus respiratorio sincicial: Patrón clínico epidemiológico en niños internados en un hospital pediátrico durante los años 2000–2013. Arch Argent Pediatr. 2014;112:397–404.
pubmed: 25192519
Marcone DN, Durand LO, Azziz-Baumgartner E, et al. Incidence of viral respiratory infections in a prospective cohort of outpatient and hospitalized children aged ≤5 years and its associated cost in Buenos Aires, Argentina. BMC Infect Dis. 2015;15:447.
doi: 10.1186/s12879-015-1213-4
pubmed: 26497393
pmcid: 4619328
Rodriguez-Martinez CE, Sossa-Briceño MP, Castro-Rodriguez JA. Direct medical costs of RSV-related bronchiolitis hospitalizations in a middle-income tropical country. Allergol Immunopathol. 2020;48:56–61.
doi: 10.1016/j.aller.2019.04.004
Moyes J, Tempia S, Walaza S, et al. The economic burden of RSV-associated illness in children aged < 5 years, South Africa 2011–2016. BMC Med. 2023;21:146.
doi: 10.1186/s12916-023-02854-2
pubmed: 37055799
pmcid: 10099882
Baral R, Mambule I, Vodicka E, et al. Estimating the economic impact of respiratory syncytial virus and other acute respiratory infections among infants receiving care at a referral Hospital in Malawi. J Pediatr Infect Dis Soc. 2020;9:738–45.
doi: 10.1093/jpids/piaa157
Bhuiyan MU, Luby SP, Alamgir NI, et al. Costs of hospitalization with respiratory syncytial virus illness among children aged <5 years and the financial impact on households in Bangladesh, 2010. J Glob Health. 2017;7:010412.
pubmed: 28702175
pmcid: 5502704
Limeres Manuel, De la Puente. ANÁLISIS DEL COMPORTAMIENTO DEL MERCADO DE MEDICAMENTOS Y POSICIONAMIENTO DEL PROGRAMA REMEDIAR. Informe final. Programa de Fortalecimiento de la Estrategia de Atención Primaria de la Salud Programa REMEDIAR ÁREA de Monitoreo y Evaluación. 2013; published online Oct. http://186.33.221.24/medicamentos//files/Analisis_del_Comportamiento_del_Mercado_de_Medicamentos.pdf .
Homedes N, Ugalde A. Improving access to pharmaceuticals in Brazil and Argentina. Health Policy Plan. 2006;21:123–31.
doi: 10.1093/heapol/czj011
pubmed: 16415339
WDI - The World by Income and Region. https://datatopics.worldbank.org/world-development-indicators/the-world-by-income-and-region.html (Accessed 17 Mar 2023).
Instituto Nacional de Estadística y Censos (INDEC). Valorización mensual de la canasta básica alimentaria y de la canasta básica total. Gran Buenos Aires, Argentina. Condiciones de vida. 2022;6(8); published online May. https://www.indec.gob.ar/uploads/informesdeprensa/canasta_06_226144AF5583.pdf .
Buendía JA, Patino DG, Sinisterra D. Cost of illness of RSV infection in a middle-income tropical country. Turk J Pediatr. 2021;63:673–82.
doi: 10.24953/turkjped.2021.04.015
pubmed: 34449150